- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Senju Pharm. Co. v. Apotex, Inc.
Claim preclusion barred plaintiffs from asserting reexamined claims that were substantially similar to the original claims that plaintiffs asserted in a first ANDA litigation.
October 16, 2012
Case Name: Senju Pharm. Co. v. Apotex, Inc., Civ. No. 11-1171-SLR, 2012 U.S. Dist. LEXIS 132219 (D. Del. Sept. 17, 2012) (Robinson, J.)
Drug Product and Patent(s)-in-Suit: gatifloxacin; U.S. Patent No. 6,333,045 (“the ’045 patent”)
Nature of the Case and Issue(s) Presented: This is the second case that plaintiffs filed against Apotex asserting infringement of the ’045 patent. In the first case, the court held that the asserted claims of the ’045 patent were invalid as obvious. Before the entry of final judgment, plaintiff filed a petition for reexamination based on Apotex’s invalidity arguments and the court’s ruling. During reexamination, plaintiffs cancelled most of the original claims and submitted new claims that contained many of the dependent limitations found in the original claims, but which were now all in one independent claim. When the PTO served a notice of intent to issue a reexamination certificate, plaintiffs, for the first time, informed the Court of the existence of the reexamination.
Plaintiffs then filed a complaint for patent infringement against Apotex based on its prior ANDA filing. Apotex moved to dismiss plaintiffs’ complaint under Fed. R. Civ. P. 12(b)(6) arguing that the claims should be dismissed on the basis of claim preclusion. In particular, Apotex argued that the claims were the same or substantially similar to the original claims. In response, plaintiffs argued that the claims were new and could not have been asserted in the prior litigation, and claim preclusion should not apply. The court agreed with Apotex.
Why Apotex Prevailed: The Court found that each patent gives rise to a cause of action, and not each claim of a patent. Applying Federal Circuit law, the only issue in dispute was whether the claims being asserted in the new action were the same or substantially similar to the claims asserted in the first action.
The court found that the new claims were merely rewrites of the original claims. In particular, the new claims were combinations of limitations that were present in the original claims. Thus, the court found that the new claims were not broader in scope than the original claims, and if anything, they were narrower than the original claims. Because the plaintiffs could have sought a narrowing interpretation of the original claims in the first action that would have been the same or substantially similar to the new claims, the court found that the new claims were, in fact, not new. Thus, the Plaintiffs cause of action was precluded by claim preclusion.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.